[go: up one dir, main page]

MA26865A1 - Composition pharmaceutique parenterale contenant un biphosphonate - Google Patents

Composition pharmaceutique parenterale contenant un biphosphonate

Info

Publication number
MA26865A1
MA26865A1 MA26732A MA26732A MA26865A1 MA 26865 A1 MA26865 A1 MA 26865A1 MA 26732 A MA26732 A MA 26732A MA 26732 A MA26732 A MA 26732A MA 26865 A1 MA26865 A1 MA 26865A1
Authority
MA
Morocco
Prior art keywords
biphosphonate
pharmaceutical composition
composition containing
parenteral pharmaceutical
parenteral
Prior art date
Application number
MA26732A
Other languages
English (en)
Inventor
Pierre Goldbach
Thomas Pfister
Anke Diederich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26865A1 publication Critical patent/MA26865A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA26732A 2000-01-20 2002-07-17 Composition pharmaceutique parenterale contenant un biphosphonate MA26865A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00101044 2000-01-20

Publications (1)

Publication Number Publication Date
MA26865A1 true MA26865A1 (fr) 2004-12-20

Family

ID=8167661

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26732A MA26865A1 (fr) 2000-01-20 2002-07-17 Composition pharmaceutique parenterale contenant un biphosphonate

Country Status (29)

Country Link
US (1) US6677320B2 (fr)
EP (1) EP1251857B1 (fr)
JP (1) JP3933933B2 (fr)
KR (1) KR100518391B1 (fr)
CN (1) CN1311835C (fr)
AR (1) AR027245A1 (fr)
AT (1) ATE318137T1 (fr)
AU (1) AU779677B2 (fr)
BR (1) BR0107755A (fr)
CA (1) CA2406798C (fr)
CY (1) CY1106482T1 (fr)
CZ (1) CZ301961B6 (fr)
DE (1) DE60117362T2 (fr)
DK (1) DK1251857T3 (fr)
ES (1) ES2258070T3 (fr)
HR (1) HRP20020594B1 (fr)
HU (1) HU229054B1 (fr)
IL (2) IL150549A0 (fr)
MA (1) MA26865A1 (fr)
MX (1) MXPA02007057A (fr)
NO (1) NO329930B1 (fr)
NZ (1) NZ519881A (fr)
PL (1) PL199784B1 (fr)
PT (1) PT1251857E (fr)
RS (1) RS50166B (fr)
RU (1) RU2238736C2 (fr)
SI (1) SI1251857T1 (fr)
WO (1) WO2001052859A1 (fr)
ZA (1) ZA200205241B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202828C (zh) * 1999-05-21 2005-05-25 诺瓦提斯公司 二膦酸在制备抑制或逆转血管发生的药物中的用途
CA2372450A1 (fr) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Preparation injectable liquide de pamidronate disodique
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
DE602004015407D1 (de) * 2003-01-17 2008-09-11 Teva Pharma Verfahren zur reduzierung des eisengehalts bei risedronat natrium
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
WO2005107714A2 (fr) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Procede de formation de microparticules comportant un bisphosphonate et un polymere
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2006019843A1 (fr) * 2004-07-15 2006-02-23 Nanobac Life Sciences Procedes et compositions pour l'administration de chelateurs de calcium, de biphosphonates et/ou de composes de citrate et leurs utilisations pharmaceutiques
US20060069068A1 (en) * 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
ATE520406T1 (de) * 2004-08-23 2011-09-15 Teva Pharma Kristalline form des ibandronat-natriums
SI1841432T1 (sl) * 2004-12-02 2011-02-28 Venus Remedies Ltd Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
AU2006210008B2 (en) 2005-02-01 2009-10-08 F. Hoffmann-La Roche Ag Ibandronate polymorph B
CA2594802C (fr) * 2005-02-01 2012-11-27 Uwe Eiermann Forme polymorphe a de l'ibandronate
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
EP1865928A1 (fr) * 2005-03-17 2007-12-19 Elan Pharma International Limited Compositions de biphosphanate nanoparticulaires
US20070088161A1 (en) * 2005-10-19 2007-04-19 Stockel Richard F Novel chelated bisphosphonates for use as pharmaceutical agents
WO2007074475A2 (fr) * 2005-12-27 2007-07-05 Natco Pharma Limited Nouvelles formes polymorphes de l'ibandronate
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090023683A1 (en) * 2007-07-16 2009-01-22 Chandrasekhar Kocherlakota Complexes comprising zoledronic acid and cyclodextrins
US8440787B2 (en) 2007-10-23 2013-05-14 Nektar Therapeutics Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CN101530415A (zh) * 2008-03-10 2009-09-16 北京德众万全医药科技有限公司 一种含有双膦酸盐的药物组合物及其制备方法
CA2724635A1 (fr) * 2008-05-19 2009-11-26 Tandem Diabetes Care, Inc. Reservoir a pompe jetable et procedes associes
US20100056483A1 (en) * 2008-09-02 2010-03-04 Ohio University Methods and compositions for the treatment and prevention of bone loss
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) * 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
EP2180003A1 (fr) * 2008-10-21 2010-04-28 Zentiva, k.s. Préparation de l'ibandronate de trisodium
EP3284494A1 (fr) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Système de pompe à perfusion portable
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PL2459176T3 (pl) 2009-07-31 2018-02-28 Grünenthal GmbH Sposób krystalizacji i biodostępność
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HRP20171201T1 (hr) * 2010-02-06 2017-10-06 Grünenthal GmbH Postupak kristalizacije i biodostupnost
US10188733B2 (en) 2010-10-22 2019-01-29 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CN103385882B (zh) * 2013-07-03 2016-02-24 江苏奥赛康药业股份有限公司 一种伊班膦酸钠注射用组合物
CN105232451B (zh) * 2015-09-27 2019-02-05 青岛斯蒂朗机电设备有限公司 一种含有唑来膦酸的注射用组合物
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
RU2657833C2 (ru) 2015-12-01 2018-06-15 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и её применение
EA033181B1 (ru) * 2015-12-09 2019-09-30 Общество С Ограниченной Ответственностью "Остерос Биомедика" Стабилизированная лекарственная форма конъюгата этидроната с цитарабином и ее применение
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique
EA030671B1 (ru) 2016-07-20 2018-09-28 Общество С Ограниченной Ответственностью "Остерос Биомедика" Препарат для лечения костных поражений, вызванных злокачественными новообразованиями
US12226451B2 (en) * 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
CA1339805C (fr) 1988-01-20 1998-04-07 Yasuo Isomura Acide (cycloalkylamino) methylenebis phosphonique et medicaments le contenant comme ingredients actif
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
US4922077A (en) 1989-01-31 1990-05-01 Raytheon Company Method of laser marking metal packages
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
CA2035179C (fr) 1990-01-31 2001-08-14 Gerald S. Brenner Composition pharmaceutique contenant des sels insolubles d'acides biphosphonique
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
DE4244422A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel
DE4244423A1 (de) 1992-12-29 1994-06-30 Boehringer Mannheim Gmbh Wasserlösliche Calciumsalze der 1-Hydroxy-3-(methylpentylamino)propan-1,1-bisphosphonsäure, ihre Herstellung und Verwendung als Arzneimittel
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
JP3672342B2 (ja) * 1994-09-26 2005-07-20 アステラス製薬株式会社 ビスホスホン酸又はその誘導体を含有する注射液とその安定化方法、及び注射液アンプル
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients

Also Published As

Publication number Publication date
CY1106482T1 (el) 2012-01-25
PL357675A1 (en) 2004-07-26
ES2258070T3 (es) 2006-08-16
IL150549A0 (en) 2003-02-12
JP2003520240A (ja) 2003-07-02
IL150549A (en) 2007-06-03
SI1251857T1 (sl) 2006-06-30
YU54802A (sh) 2006-01-16
AU779677B2 (en) 2005-02-03
RU2238736C2 (ru) 2004-10-27
EP1251857A1 (fr) 2002-10-30
CZ301961B6 (cs) 2010-08-11
MXPA02007057A (es) 2002-12-13
NO20023469L (no) 2002-07-19
HRP20020594A2 (en) 2004-08-31
WO2001052859A1 (fr) 2001-07-26
HUP0204114A2 (hu) 2003-03-28
DE60117362T2 (de) 2006-10-05
ZA200205241B (en) 2003-09-29
EP1251857B1 (fr) 2006-02-22
DE60117362D1 (de) 2006-04-27
DK1251857T3 (da) 2006-05-08
KR20020073509A (ko) 2002-09-26
JP3933933B2 (ja) 2007-06-20
PT1251857E (pt) 2006-06-30
AR027245A1 (es) 2003-03-19
NZ519881A (en) 2005-08-26
CN1311835C (zh) 2007-04-25
KR100518391B1 (ko) 2005-09-29
HRP20020594B1 (en) 2011-03-31
HUP0204114A3 (en) 2005-02-28
CA2406798A1 (fr) 2001-07-26
RS50166B (sr) 2009-05-06
ATE318137T1 (de) 2006-03-15
US20010011082A1 (en) 2001-08-02
NO20023469D0 (no) 2002-07-19
BR0107755A (pt) 2002-11-12
NO329930B1 (no) 2011-01-24
US6677320B2 (en) 2004-01-13
HU229054B1 (en) 2013-07-29
AU2516501A (en) 2001-07-31
CA2406798C (fr) 2008-04-29
PL199784B1 (pl) 2008-10-31
CN1396830A (zh) 2003-02-12

Similar Documents

Publication Publication Date Title
MA26865A1 (fr) Composition pharmaceutique parenterale contenant un biphosphonate
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
FI20001749L (fi) Farmaseuttisia koostumuksia
DK1524266T3 (da) Farmaceutisk sammensætning
IL149138A0 (en) Pharmaceutical compositions containing metformin
ATE279961T1 (de) Neue pharmazeutische zusammensetzung
NO20034014L (no) Svelgbare sammensetninger inneholdende en luktende olje
EE200200393A (et) Glüburiidi ravimkoostis
HUP0400644A3 (en) Pharmaceutical compositions containing aspirin
NO20032590D0 (no) Kjölemiddelsammensetninger inneholdende et kompatibiliseringsmiddel
IL161430A0 (en) Pharmaceutical compositions containing ecteinascidin 743
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE69911633D1 (de) Pharmazeutische zusammenstellungen die tetrahydroisoquinoleinverbindungen enthalten
IS7219A (is) Lyfjablanda sem inniheldur (R) -bíkalútamíð
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
EP1364646A4 (fr) Composition contenant du fenofibrate
EP1155624A4 (fr) Compositions de farine de copra contenant du mannose
FR2809003B1 (fr) Compositions anti-pollution a base d'anthocyanes
EP1295601A4 (fr) Composition pharmaceutique a base d'un compose anti-inflammatoire non steroide
FR2814368B1 (fr) Preparation pharmaceutique a base d'oxans
DK0988046T3 (da) Oliefri farmaceutiske sammensætninger indeholdende cyclosporin A
HUP0200390A3 (en) Pharmaceutical composition contaning amlodipine free base
SE9804128D0 (sv) A new pharmaceutical composition